 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jan 29, 2015 |
| Title |
Gene expression profiling of HDLM-2 Hodgkin lymphoma cell line after in vitro and in vivo treatment with perifosine in combination with sorafenib |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Three HL cell lines (HD-MyZ, L-540 and HDLM-2) were used to investigate the effects of perifosine and sorafenib using in vitro assays analyzing cell growth, cell cycle distribution, gene expression profiling (GEP), and apoptosis. Western blotting (WB) experiments were performed to determine whether the two-drug combination affected MAPK and PI3K/AKT pathways as well as apoptosis. Additionally, the antitumor efficacy and mechanism of action of perifosine/sorafenib combination were investigated in vivo in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. While perifosine and sorafenib as single agents exerted a limited activity against HL cells, exposure of HD-MyZ and L-540 cell lines, but not HDLM-2 cells, to perifosine/sorafenib combination resulted in synergistic cell growth inhibition (40% to 80%) and cell cycle arrest. Upon perifosine/sorafenib exposure, L-540 cell line showed significant levels of apoptosis (up to 70%, P ≤.0001) associated with severe mitochondrial dysfunction (cytochrome c, apoptosis-inducing factor release and marked conformational change of Bax accompanied by membrane translocation). Apoptosis induced by perifosine/sorafenib combination did not result in processing of caspase-8, -9, -3, or cleavage of PARP, and was not reversed by the pan-caspase inhibitor Z-VADfmk, supporting a caspase-independent mechanism of cell death. In responsive cell lines, WB analysis showed that antiproliferative and pro-apototic events were associated with dephosphorylation of MAPK and PI3K/Akt pathways. GEP analysis of HD-MyZ and L-540 cell lines, but not HDLM-2 cells indicated that perifosine/sorafenib treatment induced upregulation of genes involved in amino acid metabolism and downregulation of genes regulating cell cycle, DNA replication and cell death. In addition, in responsive cell lines, perifosine/sorafenib combination strikingly induced the expression of tribbles homologues 3 (TRIB3) both in vitro and in vivo. Silencing of TRIB3 prevented cell growth reduction induced by perifosine/sorafenib treatment. In vivo, the combined perifosine/sorafenib treatment significantly increased the median survival of NOD/SCID mice xenografted with HD-MyZ cell line as compared to controls (81 vs 45 days, P ≤.0001) as well as mice receiving perifosine alone (49 days, P ≤.03) or sorafenib alone (54 days, P ≤.007). In mice bearing subcutaneous nodules generated by HD-MyZ and L-540 cell lines but not HDLM-2 cell line, perifosine/sorafenib treatment induced significantly increased levels of apoptosis (2- to 2.5-fold, P ≤.0001) and necrosis (2- to 8-fold, P ≤.0001), as compared to controls or treatment with single agents. Perifosine/sorafenib combination resulted in strong anti-HL activity both in vitro and in vivo. These results warrant clinical evaluation of perifosine/sorafenib combined-treatment in HL patients.
|
| |
|
| Overall design |
The Hodgkin lymphoma cell line HDLM-2 was obtained from the DSMZ (Braunschweig, Germany, EU). Cells were routinely maintained in RPMI medium 1640 (Lonza, Basel, Switzerland) supplemented with 20% FBS (Lonza) and 2 mM glutamine (Lonza). Cells were maintained at 37°C in a water-saturated atmosphere of 5% CO2 in air. 10x10^6 HDLM-2 cells were seeded in 75 cm2 flask and, after 24 hrs, cells were treated with 10 µM perifosine (Aeterna Zentaris, Frankfurt, Germany, EU) and/or 5 µM sorafenib (Bayer, Berlin,
Germany, EU) in culture medium for 24 hours. At the end of treatment, cells were collected and RNA extracted.
|
| |
|
| Contributor(s) |
De Cecco L, Anichini A |
| Citation(s) |
23360848 |
| |
| Submission date |
Jul 29, 2011 |
| Last update date |
Aug 16, 2018 |
| Contact name |
Loris De Cecco |
| E-mail(s) |
loris.dececco@istitutotumori.mi.it
|
| Organization name |
IRCSS Istituto Nazionale Tumori
|
| Street address |
via Venezian 1
|
| City |
Milan |
| ZIP/Postal code |
20133 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL6947 |
Illumina HumanHT-12 V3.0 expression beadchip |
|
| Samples (12)
|
| GSM769239 |
HDLM-2_Perifosine 10µM_24hrs_2A |
| GSM769240 |
HDLM-2_Perifosine 10µM_24hrs_2B |
| GSM769241 |
HDLM-2_Perifosine 10µM_24hrs_2C |
| GSM769242 |
HDLM-2_Sorafenib 5µM_24hrs_3A |
| GSM769243 |
HDLM-2_Sorafenib 5µM_24hrs_3B |
| GSM769244 |
HDLM-2_Sorafenib 5µM_24hrs_3C |
| GSM769245 |
HDLM-2_Perifosine 10µM+Sorafenib 5µM_24hrs_4A |
| GSM769246 |
HDLM-2_Perifosine 10µM+Sorafenib 5µM_24hrs_4B |
| GSM769247 |
HDLM-2_Perifosine 10µM+Sorafenib 5µM_24hrs_4C |
|
| This SubSeries is part of SuperSeries: |
| GSE31060 |
Gene expression analysis of Hodgkin lymphoma cell lines treated with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib |
|
| Relations |
| BioProject |
PRJNA154647 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE31057_RAW.tar |
6.2 Mb |
(http)(custom) |
TAR |
| GSE31057_non_normalized_HDLM2.txt.gz |
3.8 Mb |
(ftp)(http) |
TXT |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...